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ABSTRACT 
 
Multidisciplinary tumour board (MDT) is an integral part of cancer treatment planning.  
Although no definite survival benefits have yet been shown by mostly observational studies, 
other benefits of MDT have been identified.  Traditionally the MDT involves participation of 
treating clinicians – medical, radiation and surgical oncologists.  They tend to focus on the 
cancer alone.  There is an increasing awareness that the treatment goal for cancer in older 
adults is not primarily on prolonging survival, with functional preservation and quality of life 
being particularly important for this population.  The use of comprehensive geriatric 
assessment and the input of the geriatrician in informing the oncologists regarding treatment 
decision have increasingly been shown to be beneficial.  The integration of the geriatrician 
into an MDT should be urgently explored. 
 
 
Introduction and concept of tumour board  
 
Initial treatment planning for a newly diagnosed malignancy can be complex, even if only 
considering the biology of the tumour and its anatomic extent.  Particularly when potentially 
curable, treatment may include some combination of surgery, radiation and/or 
chemotherapy, either singly, combined or sequentially. Multidisciplinary treatment planning 
incorporates the perspectives of surgical oncologists, radiation oncologists, medical 
oncologists, pathologists and radiologists, conversations which may be facilitated in a 
meeting commonly called “Tumour Board” or “Multidisciplinary Tumour Board (MDT).”    
Some tumour boards cover multiple tumour types; others are specific to certain 
malignancies, such as breast cancer or lung cancer.  Regardless of the specifics, the goal of 
an MDT is to discuss and ideally arrive at consensus on the most appropriate treatment 
options to recommend.  Traditionally, MDTs do not incorporate the expertise of geriatricians 
in treatment planning.  
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While observational studies of outcomes associated with MDT have not shown a survival 
benefit 1,2, a number of benefits have been observed.  Patients who were cared for by 
physicians who participate in an MDT were more likely to enrol in clinical trials1.This study 
did not examine patient participation by age, but given the underrepresentation of older 
adults with cancer trials, increased trial enrolment will help improve the generalisability of our 
knowledge.  Additional benefits of MDT included a greater likelihood of patients undergoing 
curative-intent lung cancer surgery for early stage cancers.  In the subgroups of patients with 
advanced colon cancer or extensive stage small cell lung cancer, mortality was reduced 
when their physicians participated in an MDT.  In another study, patients with cancer treated 
in centres where a palliative care specialist participated in the MDT were less likely to 
present to an emergency department within 30 days of the end-of-life.3  Because no 
randomized trials have been performed, it is possible that factors other than the presence or 
composition of the MDT contributed to these better outcomes, such as palliative care 
participation in MDT simply implying that those institutions also had greater access to 
palliative care specialists in general. 
 
Role of medical oncologist  
 
Because the treatments they render are delivered systemically (either orally or parenterally), 
medical oncologists tend to view cancer as a systemic disease.  Systemic therapy may be 
administered concurrently with radiation in the curative setting to improve the efficacy of the 
radiation, sequentially following surgery as an adjuvant therapy, or alone (either to lengthen 
survival when cure is not possible, or in a curative setting in selected chemosensitive 
malignancies).  Considerations for including conventional chemotherapy or newer targeted 
agents include an estimate of the patient’s risk of toxicity of therapy.  Traditional 
considerations for recommending systemic therapy include adequate organ function to 
administer a particular agent (e.g. adequate renal function for a renally cleared drug) and a 
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very basic assessment of function (e.g. ECOG performance status).  However, there is 
increasing recognition of the utility of geriatric assessment in predicting toxicity of 
chemotherapy4,5. Such tools have not yet been validated when chemotherapy is 
administered concurrently with radiation, nor for the burgeoning armamentarium of so-called 
targeted therapies.  In addition, the in-depth geriatric assessment data may not be available 
at the time of the MDT to aid in estimating the patient’s risk.   
 
Role of radiation oncologist 
 
The aim of radiotherapy is to provide local control.   Therefore, toxicity is limited to the 
treatment site.  A radiation oncologist’s primary concern is any existing limitations in that 
localised area, which may compromise an older patient’s response to a course of treatment.  
Other age-related concerns include mobility and the ability to tolerate the radiotherapy 
treatment position for a given period each day.  Radiotherapy can either be radical/curative 
or palliative, with the latter aimed at providing symptom control, rather than cure.  This may 
be recommended when a radiation oncologist judges a more curative approach to be too 
toxic, or of little benefit in the patient’s overall management. Radiotherapy is generally very 
well tolerated in older patients6, and increasingly radiation oncologists can offer shorter 
courses of treatment (hypofractionation or stereotactic radiotherapy), even in a curative 
setting, which are highly advantageous for older patients who may have difficulty accessing 
a radiotherapy facility.   
 
Role of surgical oncologist  
 
Surgery is part of a multi-modality management approach.  It aims to provide further staging 
information and to achieve cure in most cases of primary solid malignancies.  Discussion at 
an MDT is beneficial, regarding adequacy of excision (e.g. in terms of margins) and 
operative staging (e.g. nodal status), with other disciplines (e.g. pathologist and radiologist, 
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who play a significant diagnostic role), as well as with other oncologists, in order to come up 
with the best possible treatment decision after or before surgery (e.g. adjuvant or 
neoadjuvant radiation and/or systemic therapy).  Functional preservation is an important 
goal of surgery for older adults with cancer, as echoed by surgical oncologists (as opposed 
to survival alone) in an international survey7.  The MDT helps overcome one of the ongoing 
challenges i.e. to select the right patient for surgery, following which the question of how to 
optimise the patient once selected becomes vital8. 
 
Role of geriatrician  
 
The geriatric collaboration may be crucial in a MDT.  Comprehensive geriatric assessment 
(CGA) allows the team to identify the patient’s performance and to classify them as fit, unfit, 
frail.  This differentiation provides a better framework for considering the patient’s 
therapeutic options, as evidenced by a systematic review of the use of geriatric assessment 
in older adults with cancer  which showed that CGA influenced the oncologists’ treatment 
decision approximately 40-50% of the time.9  Furthermore, the geriatrician can identify the 
age-related physiological changes, the patient’s limitations and, on this basis, help reshape 
the treatment scenario and suggest better treatment options, both for the malignancy as well 
as other geriatric syndromes10. To date, several studies of CGA have not resulted in 
improved outcomes. 11-14  In the study of older adults with lung cancer by Corre et al, where 
patient treatment was stratified based on CGA, cancer-focused outcomes did not improve.  
Yet these may not be the outcomes of greatest importance to older adults.  In addition, in 
this study, no intervention was undertaken based on vulnerabilities identified by the brief 
geriatric assessment.  Thus, a geriatrician brings the perspective of focusing on improving 
the quality of life, maintaining the patient’s performance, and reducing treatment-related 
toxicity.  In addition,  interpretation of the CGA in frail older patients with cancer should be 
done by a geriatrician, who, if necessary, can follow the patient over time, recommend 
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interventions for deficits identified by CGA and collaborate with the oncologist in making 
cancer treatment recommendations.  
 
Conclusions 
 
To add to what has been said earlier, MDT may produce some intangible benefits – 
members learn from one another, hear about new or emerging knowledge, techniques or 
clinical trials, and build collaborations and rapport.  From merely conducting it as a regular 
meeting, the concept of MDT could be further developed into a multidisciplinary service or 
clinic, with treating subspecialties seeing patients concurrently or sequentially [8].  
Traditionally MDT is dominated by medical, radiation and surgical oncology subspecialists, 
who tend to put their focus on the cancer alone.  In the context of caring for older adults with 
cancer, it is pivotal to integrate geriatrics into MDT, though the precise set-up may vary 
between centres.  Along a similar line, this may pave the way to develop a dedicated 
geriatric oncology service.   There is an immense need to incorporate geriatric principles into 
all aspects of oncology care.  Adult oncologists need to become geriatric oncologists to 
adequately evaluate and care for their patient.15  As the evidence for the utility of CGA in the 
care of older adults with cancer grows, research demonstrating the benefit of incorporating 
principles of geriatrics into MDT will strengthen the imperative. 
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